IP Library Patent Application 13853475
Patent Application
App. No. 13/853,475

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/853,475
Abstract

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

Claims (21)

1 - 130 . (canceled)

131 . {1-(cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

132 . {1-(propylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

133 . {1-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

134 . 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutanecarbonitrile, or a pharmaceutically acceptable salt thereof.

135 . {1-(ethylsulfonyl)-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

136 . A composition comprising a compound of claim 131 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

137 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 131 , or pharmaceutically acceptable salt thereof.

138 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 131 , or pharmaceutically acceptable salt thereof.

139 . A composition comprising a compound of claim 132 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

140 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 132 , or pharmaceutically acceptable salt thereof.

141 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 132 , or pharmaceutically acceptable salt thereof.

142 . A composition comprising a compound of claim 133 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

143 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 133 , or pharmaceutically acceptable salt thereof.

144 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 133 , or pharmaceutically acceptable salt thereof.

145 . A composition comprising a compound of claim 134 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

146 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 134 , or pharmaceutically acceptable salt thereof.

147 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 134 , or pharmaceutically acceptable salt thereof.

148 . A composition comprising a compound of claim 135 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

149 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 135 , or pharmaceutically acceptable salt thereof.

150 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of claim 135 , or pharmaceutically acceptable salt thereof.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE OMMISSION OF SECOND RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 035292 FRAME: 0004. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 2, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 036054/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION AND INCYTE CORPORATION
Reel/Frame 035924/0004 →